Page last updated: 2024-12-07

nitrophenylgalactosides

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nitrophenylgalactosides: Includes ortho-, meta-, and para-nitrophenylgalactosides. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-nitrophenyl beta-D-galactoside : A beta-D-galactoside having a 2-nitrophenyl substituent at the anomeric position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID96647
CHEMBL ID1229648
CHEBI ID90144
SCHEMBL ID148124
MeSH IDM0014915

Synonyms (76)

Synonym
CHEMBL1229648
chebi:90144 ,
2-nitrophenyl-.beta.-d-galactopyranoside
o-nitrophenyl-.beta.-d-galactopyranoside
2-nitrophenyl .beta.-d-galactopyranoside
o-nitrophenyl .beta.-galactoside
.beta.-d-galactopyranoside, 2-nitrophenyl
o-nitrophenyl .beta.-d-galactoside
nsc-83631
o-nitrophenyl .beta.-d-galactopyranoside
369-07-3
2-nitrophenyl beta-d-galactopyranoside, >=98% (enzymatic)
SR-01000635683-1
DB01920
1-o-[o-nitrophenyl]-beta-d-galactopyranose
2-nitrophenyl-beta-d-galactopyranoside
2-(hydroxymethyl)-6-(2-nitrophenoxy)tetrahydro-2h-pyran-3,4,5-triol
smr000457368
MLS000851125
o-npg
onpg
(2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-(2-nitrophenoxy)oxane-3,4,5-triol
2-nitrophenyl beta-d-galactopyranoside
N0418
HMS2802N20
AKOS005259557
NCGC00246663-01
nsc 83631
8rfx6at9wp ,
beta-d-galactopyranoside, 2-nitrophenyl
einecs 206-716-1
o-nitrophenyl beta-d-galactopyranoside
unii-8rfx6at9wp
AKOS016008685
CCG-45946
nitrophenylgalactopyranosides
beta-d-galactopyranoside, nitrophenyl
28347-45-7
nitrophenylgalactosides
30677-14-6
einecs 250-286-8
2-nitrophenyl beta-d-galactoside
S12078
o-nitrophenyl-beta-d-galactoside
HY-15926
SCHEMBL148124
o-nitrophenyl beta-d-galacto-side
galactopyranoside, o-nitrophenyl, .beta.-d-
2-nitrophenyl hexopyranoside #
2-nitrophenyl-.beta.-.delta.-galactopyranoside
galactopyranoside, o-nitrophenyl, beta-d-
o-nitrophenyl beta-d-galactoside
(2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-(2-nitrophenoxy)tetrahydro-2h-pyran-3,4,5-triol
AC-24638
2-nitrophenyl b-d-galactopyranoside
mfcd00063255
b-d-galactoside,2-nitrophenyl(9ci)
2-nitrophenyl-i(2)-d-galactopyranoside
2-nitrophenyl beta-d-galactopyranoside, >=99.0% (hplc)
AS-62630
onpg;2-nitrophenyl -d-galactoside-(1,5)
2-nitrophenyl -d-galactopyranoside
Q287775
2-nitrophenyl-beta-d-galactopyranoside,o-nitrophenyl-beta-d-galactopyranoside;o-nitrophenyl-beta-d-galactoside;niphgal;onpg
2-nitrophenyl-b-d-galactopyranoside
M02731
o-nitrophenyl-ss-d-galactopyranoside
b-d-galactopyranoside, 2-nitrophenyl
ortho-nitrophenyl-.beta.-galactoside
1-o-(o-nitrophenyl)-beta-d-galactopyranose
o-nitrophenol .beta.-d-galactopyranoside
o-nitrophenyl-.beta.-galactopyranoside
2-nitrophenyl .beta.-d-galactoside
o-nitrophenyl ?-d-galactopyranoside
DTXSID10861907
AKOS040744333

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Active absorption in the intestine and metabolism of the beta- and alpha-anomers of the glucoside and galactoside of p-nitrophenol (p-NP) were studied to find a more suitable prodrug for poorly absorbed drugs."( Comparative study of active absorption by the intestine and disposition of anomers of sugar-conjugated compounds.
Awazu, S; Hayashi, M; Mizuma, T; Ohta, K, 1993
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Our method of analysis involves adding various amounts of purified C7 or C8 to serum preparations immunochemically depleted of C7 or C8, respectively, in order to construct dose-response curves for the action of C's terminal complex."( How complement kills E. coli. II. The apparent two-hit nature of the lethal event.
Levine, RP; Wright, SD, 1981
)
0.26
" coli than the others, indicating there was a positive synergistic effect on chlorine disinfection by prior dosing with a low level of chlorine dioxide (ClO(2))."( The synergistic effect of Escherichia coli inactivation by sequential disinfection with low level chlorine dioxide followed by free chlorine.
Chen, BY; Huo, MX; Li, JW; Yang, D; Yang, W; Zhu, SY, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
chromogenic compoundColourless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into coloured compounds. They are used in biochemical assays and in diagnosis as indicators, particularly in the form of enzyme substrates.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
beta-D-galactosideAny D-galactoside having beta-configuration at its anomeric centre.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency31.62280.28189.721235.4813AID2326
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency0.89130.251215.843239.8107AID504327
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency100.00006.309660.2008112.2020AID720709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (20)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (300)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990101 (33.67)18.7374
1990's77 (25.67)18.2507
2000's63 (21.00)29.6817
2010's55 (18.33)24.3611
2020's4 (1.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.63 (24.57)
Research Supply Index5.73 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (0.65%)4.05%
Observational0 (0.00%)0.25%
Other304 (99.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]